BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tivdak (Tisotumab Vedotin Humax-tf-adc) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tivdak (Tisotumab Vedotin Humax-tf-adc)\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06952660-2191@assetmemo.bio
DTSTAMP:20261121T010640Z
DTSTART;VALUE=DATE:20281213
DTEND;VALUE=DATE:20281214
SUMMARY:Tivdak (Tisotumab Vedotin Humax-tf-adc): Phase 4 readout est. (NCT0
 6952660)
DESCRIPTION:Tivdak (Tisotumab Vedotin Humax-tf-adc)\, phase 4\, Cervical Ca
 ncer.\nStudy: Ocular Assessments in Patients Treated With Tivdak® in Recu
 rrent or Metastatic Cervical Cancer\nEstimated primary completion: 13 Dece
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisotumab-
 vedotin-humax-tf-adc#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06952660
URL:https://assetmemo.bio/drug/tisotumab-vedotin-humax-tf-adc#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672782-2191@assetmemo.bio
DTSTAMP:20261121T010640Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Tivdak (Tisotumab Vedotin Humax-tf-adc): Phase 2 readout est. (NCT0
 7672782)
DESCRIPTION:Tivdak (Tisotumab Vedotin Humax-tf-adc)\, phase 2.\nStudy: Tiso
 tumab Vedotin in Squamous Cell Carcinoma of the Vulva\nEstimated primary c
 ompletion: March 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tisotumab-vedotin-humax-tf-adc#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07672782
URL:https://assetmemo.bio/drug/tisotumab-vedotin-humax-tf-adc#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
